Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

47.1%

8 terminated/withdrawn out of 17 trials

Success Rate

20.0%

-66.5% vs industry average

Late-Stage Pipeline

53%

9 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting6 withdrawn

Enrollment Performance

Analytics

Phase 3
7(43.8%)
Phase 2
6(37.5%)
Phase 4
2(12.5%)
N/A
1(6.3%)
16Total
Phase 3(7)
Phase 2(6)
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT04212494Not ApplicableRecruiting

Thrombus Aspiration in STEMI Patients With High Thrombus Burden

Role: collaborator

NCT04680598Unknown

Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study

Role: collaborator

NCT03722498Phase 2Withdrawn

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Role: collaborator

NCT04687163Phase 3Unknown

Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial

Role: collaborator

NCT04667351Phase 3Unknown

HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial

Role: collaborator

NCT02774187Phase 3Completed

Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

Role: collaborator

NCT03803254Phase 2Withdrawn

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Role: collaborator

NCT03780634Phase 2Withdrawn

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Role: collaborator

NCT03791918Phase 3Withdrawn

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Role: collaborator

NCT03782831Phase 2Withdrawn

TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC

Role: collaborator

NCT03744247Phase 3Withdrawn

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Role: collaborator

NCT03812770Phase 2Unknown

Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

Role: collaborator

NCT01600196Phase 4Terminated

Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus

Role: collaborator

NCT02220088Phase 2Terminated

The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

Role: collaborator

NCT02138981Phase 4Unknown

Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria

Role: collaborator

NCT03468231Phase 3Unknown

HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

Role: collaborator

NCT00493402Phase 3Completed

Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma

Role: collaborator

All 17 trials loaded